Market Place
Sourcing Support
BioCryst To Present At Upcoming Investor Conferences
28 Apr 2026 //
GLOBENEWSWIRE
BioCryst to Report Q1 2026 Financial Results on May 6
15 Apr 2026 //
GLOBENEWSWIRE
Biocryst Names Sandeep M. Menon Chief R&D Officer
06 Apr 2026 //
GLOBENEWSWIRE
Biocryst Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
03 Apr 2026 //
GLOBENEWSWIRE
Biocryst Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
04 Mar 2026 //
GLOBENEWSWIRE
BioCryst Reports Full Year 2025 Results and Business Update
26 Feb 2026 //
GLOBENEWSWIRE
BioCryst To Present At Upcoming Investor Conference
17 Feb 2026 //
GLOBENEWSWIRE
BioCryst Reports Q4 2025 Financial Results
05 Feb 2026 //
GLOBENEWSWIRE
Biocryst Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
05 Feb 2026 //
GLOBENEWSWIRE
BioCryst Berotralstat Prelim `25 Rev $601M +37% YoY Beats
12 Jan 2026 //
GLOBENEWSWIRE
Biocryst To Present At J.P. Morgan Healthcare Conference
06 Jan 2026 //
GLOBENEWSWIRE
Biocryst Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
06 Jan 2026 //
GLOBENEWSWIRE
BioCryst Awards Inducement Grants Under Nasdaq Equity Rule
04 Dec 2025 //
GLOBENEWSWIRE
Biocryst Gets Early HSR Approval For Astria Buyout
03 Dec 2025 //
GLOBENEWSWIRE
Biocryst Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
05 Nov 2025 //
GLOBENEWSWIRE
Biocryst To Present at Upcoming Investor Conference
05 Nov 2025 //
GLOBENEWSWIRE
Biocryst To Release Q3 2025 Financial Results On Nov 3
20 Oct 2025 //
GLOBENEWSWIRE
Biocryst Finalizes European Orladeyo Sale
01 Oct 2025 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
03 Sep 2025 //
GLOBENEWSWIRE
BioCryst Set to Speak at Investor Conference
21 Aug 2025 //
GLOBENEWSWIRE
BioCryst Announces Dr. Helen Thackray`s Departure
11 Aug 2025 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
06 Aug 2025 //
GLOBENEWSWIRE
BioCryst Reports Q2 2025 Financials and Updates on Business
04 Aug 2025 //
GLOBENEWSWIRE
Charlie Gayer to Replace Jon as BioCryst CEO in December
31 Jul 2025 //
GLOBENEWSWIRE
BioCryst`s Q2 2025 Financial Results Due August 4
21 Jul 2025 //
GLOBENEWSWIRE
BioCryst to Present Patient-focused Research at US HAEA Summit
09 Jul 2025 //
GLOBENEWSWIRE
BioCryst issues inducement grants per Nasdaq Listing Rule
03 Jul 2025 //
GLOBENEWSWIRE
BioCryst Sells European ORLADEYO Business to Neopharmed Gentili
27 Jun 2025 //
GLOBENEWSWIRE
BioCryst Presents Long-term ORLADEYO Data at EAACI
16 Jun 2025 //
GLOBENEWSWIRE
BioCryst Gets ORLADEYO Reimbursement in Major European Countries
06 Jun 2025 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
03 Jun 2025 //
GLOBENEWSWIRE
BioCryst to Present New Data at 2025 EAACI Meeting
02 Jun 2025 //
GLOBENEWSWIRE
BioCryst Shows Orladeyo Reduces HAE Attacks in All Ages
30 May 2025 //
GLOBENEWSWIRE
BioCryst Reports ORLADEYO Cuts HAE Attacks in Real World
16 May 2025 //
GLOBENEWSWIRE
BioCryst’s Orladeyo NDA Accepted for Children with HAE by FDA
14 May 2025 //
GLOBENEWSWIRE
BioCryst Reports Q1 2025 Financial Results and Business Update
05 May 2025 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants under Nasdaq Rule 5635(c)(4)
02 May 2025 //
GLOBENEWSWIRE
BioCryst to Present at Upcoming Investor Conferences
30 Apr 2025 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
04 Apr 2025 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
06 Mar 2025 //
GLOBENEWSWIRE
BioCryst’s Orladeyo Shows APeX-P Trial Results In Pediatric HAE
24 Feb 2025 //
GLOBENEWSWIRE
BioCryst Reports Q4 and Full Year 2024 Results and Milestones
24 Feb 2025 //
GLOBENEWSWIRE
BioCryst to Present at Upcoming Investor Conferences
19 Feb 2025 //
GLOBENEWSWIRE
BioCryst Launches ORLADEYO® (berotralstat) in Portugal
12 Feb 2025 //
GLOBENEWSWIRE
BioCryst To Present ORLADEYO® Pediatric Trial Data At AAAAI
10 Feb 2025 //
GLOBENEWSWIRE
BioCryst to Report Q4 2024 Financial Results on February 24
10 Feb 2025 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
04 Feb 2025 //
GLOBENEWSWIRE
Biocryst Reports $437M Orladeyo® Revenue (+34 Percent Y-O-Y)
10 Jan 2025 //
GLOBENEWSWIRE
BioCryst to Present at 43rd Annual J.P. Morgan Conference
07 Jan 2025 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
04 Dec 2024 //
GLOBENEWSWIRE
BioCryst Launches ORLADEYO® (berotralstat) in Ireland
18 Nov 2024 //
GLOBENEWSWIRE
BioCryst Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
05 Nov 2024 //
GLOBENEWSWIRE
BioCryst Reports Q3 2024 Results and Business Update
04 Nov 2024 //
GLOBENEWSWIRE
BioCryst to Report Third Quarter 2024 Financial Results on November 4
21 Oct 2024 //
GLOBENEWSWIRE
BioCryst To Present Evidence Showing Reduced Visits After ORLADEYO®
14 Oct 2024 //
GLOBENEWSWIRE
BioCryst Presents HAE Prophylaxis Data At ACAAI 2024 Meeting
10 Oct 2024 //
GLOBENEWSWIRE
BioCryst Reports Grants Under Nasdaq Rule 5635(c)(4)
03 Oct 2024 //
GLOBENEWSWIRE
BioCryst Begins Phase 1 Trial for Netherton Syndrome
02 Oct 2024 //
GLOBENEWSWIRE
U.S. Government Awards BioCryst $69 Million RAPIVAB Contract
30 Sep 2024 //
GLOBENEWSWIRE
BioCryst Completes pCPA Negotiations for ORLADEYO®
17 Sep 2024 //
GLOBENEWSWIRE
